Journal article
Improvements in outcomes in older patients with mantle cell lymphoma are associated with improvements across multiple lines of therapy
Clinical lymphoma, myeloma and leukemia, Vol.25(6), pp.e383-e392.e1
06/2025
DOI: 10.1016/j.clml.2025.01.008
PMID: 39919998
Abstract
Background
Survival in mantle cell lymphoma (MCL) has improved over time, with one potential reason being approval of new therapies. We hypothesized that access to multiple new agents with non-overlapping mechanisms of action would result in significant improvements in overall survival.
Patients and Methods
Patients ages >65 and diagnosed with MCL between 2002 and 2019 were identified using SEER-Medicare linked database. Lines of therapy were determined using billing codes. Overall survival 1 (OS1) was defined as time of initial therapy to death, while OS2 was defined as time of second-line therapy to death. Time to next therapy (TTNT) was defined as time from first-line therapy to death or start of second-line therapy. Analyses were stratified by both year of diagnosis and year of treatment categories.
Results
In total, 5,441 patients were included; 4,382 patients (79.5%) had claims for first-line regimens and 1,538 (34.1%) for second-line regimens. In the first-line, use of rituximab-bendamustine (BR) increased from <2% of patients diagnosed between 2002-2005 to 54% between 2014-2019. BTK-inhibitor (BTKi)-containing regimens, approved in 2013 for use in the second-line, accounted for 8% of first-line and 54% of second-line regimens among those diagnosed between 2014-2019. OS1 was significantly improved across year of diagnosis categories (P<0.0001), with improvements also seen in TTNT and OS2.
Conclusion
We observed improvements in both OS1 and TTNT over time, which may correlate with increased BR and BTKi use as first-line agents. Unexpectedly, OS2 improvements were more modest. These data support the need for continued development of new therapies in MCL.
Details
- Title: Subtitle
- Improvements in outcomes in older patients with mantle cell lymphoma are associated with improvements across multiple lines of therapy
- Creators
- Danny Luan - Weill Cornell MedicineNeela Easwar - Weill Cornell MedicineZhengming Chen - Weill Cornell MedicineBrian Link - University of IowaYucai Wang - Mayo ClinicMatthew Maurer - Weill Cornell MedicineBrad Kahl - Washington University in St. Louis School of MedicineLaura Pinheiro - Weill Cornell MedicineJohn Leonard - Weill Cornell MedicinePeter Martin - Weill Cornell Medicine
- Resource Type
- Journal article
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.25(6), pp.e383-e392.e1
- DOI
- 10.1016/j.clml.2025.01.008
- PMID
- 39919998
- NLM abbreviation
- Clin Lymphoma Myeloma Leuk
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Publisher
- CIG MEDIA GROUP, LP
- Language
- English
- Electronic publication date
- 01/2025
- Date published
- 06/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984775260102771
Metrics
2 Record Views